Antigen-specific T cells in autoimmune diseases with a focus on multiple sclerosis and experimental allergic encephalomyelitis

Cellular and Molecular Life Sciences

Volumn 56, Issue 1-2, 1999, Pages 5-21

  Xiao, B G ^a   Link, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antigen specific T cells; Autoantigen; Autoimmune disease; Experimental allergic encephalomyelitis; Immunity; Immunotherapy; Multiple sclerosis; Self tolerance

Indexed keywords

AUTOANTIGEN;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DENDRITIC CELLS; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MODELS, BIOLOGICAL; MUCOUS MEMBRANE; MULTIPLE SCLEROSIS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; VACCINES;

ANIMALIA;

EID: 0033215144     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050002     Document Type: Review

References (134)

1. Bach J. F., Koutouzov S. and Endert P. M. van (1998) Are there unique autoantigens triggering autoimmune diseases? Immunol. Rev. 164: 139-155
2. Sun J. B., Olsson T., Wang W. Z., Xiao B. G., Kostulas V., Fredrikson S. et al. (1991) Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur. J. Immunol. 21: 1461-1468
3. Stinissen P., Raus J. and Zhang J. (1997) Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit. Rev. Immunol. 17: 33-75
4. Sun J. B., Link H., Olsson T., Xiao B. G., Andersson G. and Ekre H. P. (1991) T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J. Immunol. 146: 1490-1495
5. Lu C. Z., Fredrikson S., Xiao B. G. and Link H. (1993) Interleukin-2 secreting cells in multiple sclerosis and controls. J. Neurol. Sci. 120: 99-106
6. Kerlero de Rosbo N., Milo R., Lees M. B., Berger D., Bernard C. C. and Ben-Nun A. (1993) Reactivity to myelin antigen in multiple sclerosis: peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J. Clin. Invest. 92: 2602-2608
7. Kerlero de Rosbo N. and Ben-Nun A. (1998) T-cell responses to myelin antigens in multiple sclerosis: relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. J. Autoimmunity 11: 287-299
8. Kojima K., Berger T., Lassmann H., Hinze-Selch D., Zhang Y., Gehrmann J. et al. (1994) Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecules, a calcium binding protein of astroglia. J. Exp. Med. 180: 817-829
9. Mackenzie-Graham A., Pribyl T. M., Kim S., Porter V. R., Campagnoni A. T. and Voskuhl R. R. (1997) Myelin protein expression is increased in lymph nodes of mice with relapsing experimental autoimmune encephalomyelitis. J. Immunol. 159: 4602-4610
10. Voskuhl R. R. (1998) Myelin protein expression in lymphoid tissues: implication for peripheral tolerance. Immunol. Rev. 164: 81-92
11. Zinkernagel R. M., Ehl S., Aichele P., Oehen S., Kundig T. and Hengartner H. (1997) Antigen location regulates immune response in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev. 156: 199-209
12. Lehmann P. V., Targoni O. S. and Forsthuber T. G. (1998) Shifting T-cell activation thresholds in autoimmunity and determinant spreading. Immunol. Rev. 164: 53-62
13. Wekerle H., Bradl M., Linington C., Kaab G. and Kojima K. (1996) The shaping of the brain-specific T lymphocyte repertoire in the thymus. Immunol. Rev. 149: 231-243
14. Schwartz R. H. (1996) Models of T cell anergy: is there a common molecular mechanism? J. Exp. Med. 184: 1-8
15. Cohen I. R. and Young D. B. (1991) Autoimmunity, microbial immunity and the immunological homunculus. Immunol. Today 12: 105-111
16. CohenI.R. (1992) The cognitive paradigm and the immunological homunculus. Immunol. Today 13: 490-494
17. SteinmanL. and Conlon P. (1997) Virus damage and the breakdown of self-tolerance. Nat. Med. 3: 1085-1087
18. Rosa F. D. and Barnaba V. (1998) Persisting viruses and chronic inflammation: understanding their relation to autoimmunity. Immunol. Rev. 164: 17-27
19. Fugier V. I., Servet D. C., Rivailler P., Rissoan M. C., Liu Y. J. and Rabourdin C. C. (1997) Measles virus suppresses cell mediated immunity by interfering with the survival and functions of dendritic and T cells. J. Exp. Med. 186: 813 823
20. Grosjean I., Caux C., Bella C., Berger I., Wild F., Banchereau J. et al. (1997) Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T cells. J. Exp. Med. 186: 801-812
21. Barnaba V. (1996) Viruses, hidden self-epitopes and autoimmunity. Immunol. Rev. 152: 47-66
22. Elson C. J., Barker R. N., Thompson S. J. and Williams N. A. (1995) Immunologically ignorant autoreactive T cells, epitope spreading and repertoire limitation. Immunol. Today 16: 72-76
23. Schwartz R. H. (1990) A cell culture model for T lymphocyte clonal anergy. Science 248: 1349-1356
24. Janeway C. A. Jr. and Bottomly K. (1994) Signals and signs for lymphocyte responses. Cell 76: 275-285
25. Theofilopoulos A. N. (1995) The basis of autoimmunity. 1. Mechanisms of aberrant self-tolerance. Immunol. Today 16: 90-98
26. Fujinami R. S. and Oldstone M. B. (1985) Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230: 1043-1045
27. Georgopoulos C. and McFarland H. (1993) Heat shock proteins in multiple sclerosis and other autoimmune diseases. Immunol. Today 14: 373-375
28. Waltmas T. L. and Bluestone J. A. (1998) CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J. Immunol. 168: 3855-3860
29. Van Parijs L., Perez V. L., Biuckians A., Maki R. G., London C. A. and Abbas A. K. (1997) Role of interleukin 12 and costimulation in T cell anergy in vivo. J. Exp. Med. 186: 1119-1128
30. Ushio H., Tsuji R. F., Szczepanik M., Kawamoto K., Matsuda H. and Askenase P. W. (1998) IL-12 reverse established antigen-specific tolerance of contact sensitivity by affecting costimulatory molecules B7-1 (CD80) and B7-2 (CD86). J. Immunol. 160: 2080-2088
31. Koh J. S. and Levine J. S. (1997) Apoptosis and autoimmunity. Curr. Opin. Nephrol. Hypertens. 6: 259-266
32. Goodnow C. C. (1996) Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc. Natl. Acad. Sci. USA 93: 2264-2271
33. Limmer A., Sacher T., Alferink J., Kretschmar M., Schönrich G., Nichterlein T. et al. (1998) Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur. J. Immunol. 28: 2395-2406
34. St. Groth B. F. de (1998) The evolution of self-tolerance: a new cell arises to meet the challenge of self-reactivity. Immunol. Today 19: 448-454
35. Banchereau A. and Steinman R. M. (1998) Dendritic cells and the control of immunity. Nature 392: 245-252
36. Clare-Salzler M. J., Brooks J., Chai A., Van Herle K. and Anderson C. (1992) Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J. Clin. Invest. 90: 741-748
37. Steinbrink K., Wölfl M., Jonuleit H., Knop J. and Enk A. H. (1997) Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159: 4772- 4780
38. Liu L., Rich E. E., Inobe J. I., Chen W. and Weiner H. I., (1998) Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4 + T cells to secrete IL-4. Int. Immunol. 10: 1017-1026
39. Viney J. L., Mowat A. M., O'Malley J. M., Williamson E. and Fanger N. A. (1998) Expanding dendritic cells in vivo enhances the induction of oral tolerance. J. Immunol. 160: 5815-5825
40. Ludewig B., Odermatt B., Landmann S., Hengartner H. and Zinkernagel R. M. (1998) Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J. Exp. Med. 188: 1493-1501
41. Kojima K., Reindl M., Lassmann H., Wekerle H. and Linington C. (1997) The thymus and self-tolerance: coexistence of encephalitogenic S 100 beta-specific T cells and their nominal autoantigen in the normal adult rat thymus. Int. Immunol. 9: 897-904
42. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T. et al. (1996) Treatment of experimental encephalomyelitis with a peptide analogue of myclin basic protein. Nature 379: 343-346
43. Steinman L. (1996) A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc. Natl. Acad. Sci. USA 93: 2253-2256
44. Yednock T., Cannon C., Fritz L., Sanchez-Madrid F., Steinman L. and Karin N. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356: 63-66
45. Baron J. L., Madri J. A., Ruddle N. H., Hashim G. and Janeway C. A. Jr. (1993) Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177: 57-68
46. Gijbels K., Galardy R. E. and Steinman L. (1994) Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J. Clin. Invest. 94: 2177-2182
47. Gijbels K., Masure S., Carton H. and Opdenakker G. (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41: 29-34
48. Heber-Katz F., and Acha-Orbea H. (1989) The V-region hypothesis: evidence from autoimmune encephalomyelitis. Immunol. Today 10: 164-169
49. Burns F. R., Li X., Shen N., Offiner H., Chou Y. K., Vandenbark A. A. et al. (1989) Both rat and mouse T cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar Vα and Vβ chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. J. Exp. Med. 169: 27-39
50. Kuchroo V. K., Martin C. A., Greer J. A., Ju S. T., Sobel R. A. and Dorf M. E. (1993) Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clines to mediate experimental allergic encephalomyelitis. J. Immunol. 151: 4371-4382
51. Chen Y., Kuchroo V. K., Inobe J. I., Hafler D. A. and Weiner H. L. (1994) Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265: 1237-1240
52. Correale J., Gilmore W., McMillan M., Li S., McCarthy K., Le T. et al. (1995) Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J. Immunol. 154: 2959-2968
53. Laman J. D., Thompson E. J. and Kappos L. (1998) Balancing the Th1/Th2 concept in multiple sclerosis. Immunol. Today 19: 489-490
54. LafailleJ.J., Van de KeereF., HsuA.L., BaronJ.L., HaasW. and RaineC.S. (1997) Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease.J. Exp. Med. 186: 307-312
55. Pakala S. V., Kurrer M. O. and Katz J. D. (1997) T helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice. J. Exp. Med. 186: 299-306
56. Liu J., Marino M. W., Wong G., Grail D., Dunn A., Bettadapura J. et al. (1998) TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyclination. Nat. Med. 4: 78-83
57. Tuohy V. K., Yu M., Yin L., Kawczak J. A., Johnson J. M. and Mathisen P. M. (1998) The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev. 164: 93-100
58. Vanderlugt C. L., Begolka W. S., Neville K. L., Katz-Levy Y., Howard L. M. and Eagar T. N. (1998) The functional significance of epitope spreading and its regulation by costimulatory molecules. Immunol. Rev. 164: 63-72
59. Miller S. D. (1997) Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat. Med. 3: 1133-1136
60. Miller S. D., Vanderlugt C. L., Lenschow D. J., Pope J. G., Dal Canto M. C. and Bluestone J. A. (1995) Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of in murine EAE. Immunity 3: 739-745
61. Yu M., Johnson J. M. and Tuohy V. K. (1996) A predictable sequential determinant spreading cascade invariably accompanies progression: a basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med. 183: 1777-1788
62. Cumberbatch M. and Kimber I. (1995) Tumor necrosis factor-alpha is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization. Immunology 84: 31-35
63. Steinman R. M. (1991) The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9: 271-296
64. Sallusto F., Cella M., Danieli C. and Lanzavecchia A. (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182: 389-400
65. LarsenC.P., RitchieS.C., Pearson T,C., LinslevP.S. and LowryR.P. (1992) Functional expression of the costimulatory molecules, B7/BB1, on murine dendritic cell populations.J. Exp. Med. 176: 1215-1220
66. Weiss A. and Litman D. R. (1994) Signal transduction by lymphocyte antigen receptor. Cell 76: 263-274
67. DeBenedette M. A., Shahinian A., Mak T. W. and Watts T. H. (1997) Costimulation of CD28 - T lymphocytes by 4-IBB ligand. J. Immunol. 158: 551-559
68. Reinhold M. I., Lindberg F. P., Kersh G. J., Allen P. M. and Brown E. J. (1997) Costimulation of T cell activation by integrin-associated protein (CD7) is an adhesion-dependent, CD28-independent signaling pathway. J. Exp. Med. 185: 1-11
69. Tai X. G., Yashiro Y., Abe R., Toyooka K., Wood C. R., Morris J. et al. (1996) A role for CD9 molecules in T cell activation. J. Exp. Med. 184: 753-758
70. Bonay M., Bouchonnet F., Lecossier D., Boumsell L., Soler P., Grodet A. et al. (1997) Activation of T cells through an antigen-independent alternative pathway induces precocious sensitivity to Fas-induced apoptosis. Immunol. Lett. 59: 107-113
71. Mehta-Damani A., Markowicz S. and Engleman E. G. (1995) Generation of antigen-specific CD4+ T cell lines from naive precursors. Eur. J. Immunol. 25: 1206-1211
72. Grewal I. S., Xu J. and Flavell R. A. (1995) Impairment of antigen-specific T cell priming in mice lacking CD40 ligand. Nature 378: 617-620
73. Pape K. A., Kearney E. R., Khoruts A., Mondino A., Merica R., Chen Z. M. et al. (1997) Use of adoptive transfer of T-cell-antigen-receptor-transgenic T cells for the study of T-cell activation in vivo. Immunol. Rev. 156: 67-78
74. Tivol E. A., Borriello F., Schweitzer A. N., Lynch W. P., Bluestone J. A. and Sharpe A. N. (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547
75. Waterhouse P., Penninger J. M., Timms E., Wakeham A., Shahinian A., Lee K. P. et al. (1995) Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270: 985-988
76. Karandikar N., Vanderlugt C. L., Walunas T. L., Miller S. D. and Bluestone J. A. (1996) CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184: 783-788
77. Gribben J. G., Freeman G. J., Boussiotis V. A., Rennert P., Jellis C. L., Greenfield E. et al. (1994) CTLA-4 mediated costimulation induces apoptosis of activated human T lymphocytes. Proc. Natl. Acad. Sci. USA 92: 811-815
78. Krummel M. F. and Allison J. P. (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183: 2533-2540
79. Liblau R., Tisch R., Shokat K., Yang X., Dumont N., Goodnow C. C. et al. (1996) Intravenous injection of soluble antigen induces thymic and peripheral T-cell apoptosis. Proc. Natl. Acad. Sci. USA 93: 3031-3036
80. Alferink J., Schittek B., Schonrich G., Hammerling G. J. and Arnold B. (1995) Long life span of tolerant T cells and the role of antigen in maintenance of peripheral tolerance. Int. Immunol. 7: 331-336
81. Sloan-Lancaster J., Evavild B. D. and Allen P. M. (1993) Induction of T cell anergy by altered T cell receptor ligand on live antigen-presenting cells. Nature 363: 156-159
82. LaSalle J. M., Tolentino P. J., Freeman G. J., Nadler L. M. and Hafler D. A. (1992) Early signaling defects in human T cells anergized by T cell presentation of autoantigen. J. Exp. Med. 176: 177-186
83. HowellM.D., WintersS.T., OlecT., PowellH.C., CarloD.J. and BrostoffS.W. (1989) Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 246: 668-670
84. Vandenbark A. A., Hashim G. A. and Offner H. (1989) Immunization with a synthetic T cell receptor V region peptide protects against experimental autoimmune encephalomyelitis. Nature 341: 541-544
85. Bourdette D. N., Whitham R. H., Chou Y. K., Morrison W. J., Atherton J., Kenny C. et al. (1994) Immunity to T cell receptor peptides in multiple sclerosis. I Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides. J. Immunol. 152: 2510-2519
86. Chou Y., Morrison W. J., Weinberg A. D., Dedrick R., Whitham R., Bourdette D. N. et al. (1994) Immunity to T cell receptor peptides in multiple sclerosis. II. T cell recognition vβ5.2 and Vβ6.1 CDR2 peptides. J. Immunol. 152: 2520-2529
87. Liblau R., Tisch R., Bercovici N. and McDevitt H. O. (1997) Systemic antigen in the treatment of T-cell-mediated autoimmune diseases. Immunol. Today 18: 599-604
88. Ishigami T., White C. A. and Pender M. P. (1998) Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral organs. Eur. J. Immunol. 28: 1626-1635
89. Tan L. J., Kennedy M. K. and Miller S. D. (1992) Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. II. Fine specificity of effector T cell inhibition. J. Immunol. 148: 2748-2755
90. Rocken M. and Shevach E. M. (1996) Immune deviation the third dimension of nondeletional T cell tolerance. Immunol. Rev. 149: 175-194
91. Nicholson L. B., Greer J. M., Sobel R. A., Lees M. B. and Kuchroo V. K. (1995) An altered peptide ligand mediates deviation and prevents autoimmune encephalomyelitis. Immunity 3: 397-405
92. Jewell S. D., Gienapp I. E., Cox K. L. and Whitacre C. C. (1998) Oral tolerance as therapy for experimental autoimmune encephalomyelitis and multiple sclerosis: demonstration of T cell anergy. Immunol. Cell. Biol. 76: 74-82
93. Link H. and Xiao B. G. (1998) Transforming growth factor beta. In: Encyclopedia of Immunology, vol. 4, 2nd edn. pp. 2392-2398, Delves P. J. and Roitt I. (eds), Academic Press, London
94. Critchfield J. M. and Lenardo M. J. (1995) Antigen-induced programmed T cell death as a new approach to immune therapy. Clin. Immunol. Immunopathol. 75: 13-19
95. Xiao B. G. and Link H. (1997) Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin. Immunol. Immunopathol. 85: 119-128
96. Wang Z. Y., Qiao J. and Link M. (1993) Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J. Neuroimmunol. 44: 209-214
97. Ma C. G., Zhang G. X., Xiao B. G., Wang Z. Y., Link H. and Olsson T. (1996) Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-γ-expressing Th1-like cells and up-regulation of TGF-β mRNA in mononuclear cells. Ann. NY Acad. Sci. 778: 273-287
98. Hafler D. A., Kent S. C., Pietrusewicz M. J., Khoury S. J., Weiner H. L. and Fukaura H. (1997) Oral administration of myelin induces antigen-specific TGF-β1 secreting T cells in patients with multiple sclerosis. Ann. NY Acad. Sci. 835: 120-131
99. Miller S. D., Tan L. J., Kennedy M. K. and Dal Canto M. C. (1991) Specific immunoregulation of the induction and effector stages of relapsing EAE via neuroantigen-specific tolerance induction. Ann. NY Acad. Sci. 636: 79-94
100. Miller S. D., Tan L. J., Pope L., McRae B. I., and Karpus W. J. (1992) Antigen-specific tolerance as a therapy for experimental autoimmune encephalomyelitis. Int. Rev. Immunol. 9: 203-222
101. Bai X. F., Shi F. D., Xiao B. G., Li H. L., Meide P. H. van der and Link H. (1997) Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-β mRNA. J. Neuroimmunol. 80: 65-75
102. Weiner H. L. (1997) Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today 18: 335-343
103. Barnett M. L., Kremer J. M., St. Clair E. W., Clegg D. O., Furst D., Weisman M. et al. (1998) Treatment of rheumatoid arthritis with oral type II collagen: results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 41: 290-297
104. Nussenblatt R. B., Gery I., Weiner H. L., Ferris F. L., Shiloach J., Remaley N. et al. (1997) Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am. J. Ophthalmol. 123: 583-592
105. Vandenbark A. A., Vainiene M., Ariail K., Miller S. D. and Offiner H. (1996) Prevention and treatment of relapsing autoimmune encephalomyelitis with myelin peptide-coupled splenocytes. J. Neurosci. Res. 45: 430-438
106. Zhang J., Medaer R., Stinissen P., Hafler D. and Raus J. (1993) MHC restricted clonotypic depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 261: 1451-1454
107. Medae R., Stinissen P., Truyen L., Raus J. and Zhang J. (1995) Depletion of myelin basic protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet 346: 807-808
108. Borghans J. A., De Boer R. J., Sercarz E. and Kumar V. (1998) T cell vaccination in experimental autoimmune encephalomyelitis: a mathematical model. J. Immunol. 161: 1087-1093
109. Vandenbark A. A., Chou Y. K., Whitham R., Mass M., Buenafe A., Liefeld D. et al. (1996) Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat. Med. 2: 1109-1116
110. Javed N. H., Gienapp I. E., Cox K. L. and Whitacre C. C. (1995) Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis. J. Immunol. 155: 1599-1605
111. Miller A., Al-Sabbagh A., Santos L. M. B., Das M. O. and Weiner H. L. (1993) Epitopes of myclin basic protein that trigger TGF-β release after oral tolerance are distinct from encephalitogenic epitopes and mediate epitope-driven by-stander suppression. J. Immunol. 151: 7307-7315
112. Metzler B. and Wraith D. C. (1992) Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int. Immunol. 5: 1159-1165
113. Liu J. Q., Bai X. F., Shi F. D., Xiao B. G., Li H. L., Levi M. et al. (1998) Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99. Int. Immunol. 10: 1139-1148
114. Zhang G X., Shi F. D., Zhu J., Xiao B. G., Levi M., Wahren B. et al. (1998) Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis. J. Neuroimmunol. 85: 96-101
115. Zou L. P., Zhu J., Deng G. M., Levi M., Wahren B., Diab A. et al. (1998) Treatment with P2 protein peptide 57-81 by nasal route is effective in Lewis rat experimental autoimmune neuritis, J. Neuroimmunol. 85: 137-145
116. Wildner G., Hunig T. and Thurau S. R. (1996) Orally induced peptide-specific γ/δ TCR + cell suppress experimental autoimmune uveitis. Eur. J. Immunol. 26: 2140-2148
117. Staines N. A., Narper N., Ward F. J., Malmstrom V., Holmdahl R. and Bansal S. (1996) Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (C II) expressing a dominant T cell epitope. Clin. Exp. Immunol. 103: 368-375
118. Khare S. D., Krco C. J., Pawelski J. R., Griffiths M. M., Luthra H. S. and David C. S. (1994) Oral administration of human collagen peptide 250-270 suppresses collagen-induced arthritis in DBA 1 mice by inhibiting a Th1 response. Arthritis Rheum. 37: S398
119. Gaur A., Wiers B., Liu A., Rothbard J. and Fathman C. G. (1992) Amelioration of autoimmune encephalomyelitis by myclin basic protein synthetic peptide-induced anergy. Science 258: 1491-1494
120. Sasamoto Y., Kawano Y. I., Bouligny R., Wiggert B., Chader G. J. and Gery I. (1992) Immunomodulation of experimental autoimmune uveoretinitis by intravenous injection of uveitogenic peptides. Invest. Ophthalmol. Vis. Sci. 33: 2641-2649
121. Fuller B. E., Okayasu I., Simon L. L., Giraldo A. A. and Kong Y. M. (1993) Characterization of resistance to murine experimental autoimmune thyroiditis: duration and afferent action of thyroglobulin- and TSH-induced suppression. Clin. Immunol. Immunopathol. 69: 60-68
122. Tian J., Clare-Salzler M., Herschenfeld A., Middleton B., Newman D., Mueller R. et al. (1996) Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat. Med. 2: 1348-1353
123. Nussenblatt R. B., Caspi R. R., Mahdi R., Chan C. C., Roberge F., Lider O. et al. (1990) Inhibition of S-Ag induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-Ag. J. Immunol. 144: 1689-1695
124. Dick A. D., Cheng Y. F., McKinnon A., Liversidge J. and Forrester J. V. (1993) Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. Br. J. Ophthalmol. 77: 171-175
125. Peterson K. E. and Braley-Mullen H. (1995) Suppression of murine experimental autoimmune thyroiditis by oral administration of porcine thyroglobulin. Cell. Immunol. 166: 123-130
126. Daniel D. and Wegmann D. R. (1996) Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. USA 93: 956-960
127. Matsumoto Y., Tsuchida M., Hanawa H. and Abo T. (1994) T cell receptor peptide therapy for autoimmune encephalomyelitis: stronger immunization is necessary for effective vaccination. Cell. Immunol. 153: 468-478
128. Rosloniec E. F., Brand D. D., Whittington K. B., Stuart J. M., Ciubotaru M. and Ward E. S. (1995) Vaccination with a recombinant V alpha domain of a TCR prevents the development of collagen-induced arthritis. J. Immunol. 155: 4504-4511
129. Formby B. and Shao T. (1993) T cell vaccination against autoimmune diabetes in nonobese diabetic mice. Ann. Clin. Lab. Sci. 23: 137-147
130. Beraud E., Kotake S., Caspi R. R., Oddo S. M., Chan C. C., Gery I. et al. (1992) Control of experimental autoimmune uveoretinitis by low dose T cell vaccination. Cell. Immunol. 140: 112-122
131. Warren K. G. and Catz I. (1995) Administration of myelin basic protein synthetic peptides to multiple sclerosis patients. J. Neurol. Sci. 133: 85-94
132. Gold D. P., Smith R. A., Golding A. B., Morgan E. E., Dafashy T., Nelson J. et al. (1997) Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCR beta 6 CDR2 peptide. J. Neuroimmunol. 76: 29-38
133. Moreland L. W., Morgan E. F., Adamson T. C., Fronek Z., Calabrese L. H., Cash J. M. et al. (1998) T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14 and Vbeta17 peptides. Arthritis Rheum. 41: 1919-1929
134. Laar J. M. van, Vries R. R. de and Breedveld F. C. (1993) T cell vaccination in humans: the experience in rheumatoid arthritis. Clin. Exp. Rheumatol. 8: S59-S62